Conventional cardiovascular risk factors in HIV infection: How conventional are they?

Current Opinion in HIV and AIDS

Volumn 3, Issue 3, 2008, Pages 214-219

  Sabin, Caroline A ^a   Worm, Signe W ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Age; Cardiovascular disease; Metabolic syndrome; Risk factors; Smoking

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR;

AGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEVELOPING COUNTRY; DYSLIPIDEMIA; FAMILY HISTORY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; POPULATION; POPULATION RESEARCH; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SMOKING;

EID: 42049115899     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3282f6a613     Document Type: Review

References (48)

1. UNAIDS. AIDS Epidemic Update; 2007. http://www.unaids.org/en/HIV_data/ 2007EpiUpdate/default.asp. [Accessed 6 February 2008]
2. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Changes in risk factors for cardiovascular disease and use of lipid-lowering drugs over time among HIV-infected individuals and impact on myocardial infarction. Clin Infect Dis (in press).
3. Grabar S, Weiss L, Costagliola D. HIV infection in older patients in the HAART era. J Antimicrob Chemother 2006; 57:4-7.
4. Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study. Response to combination: variation by age. AIDS (in press)
5. Friis-Moller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy: results from the DAD study. AIDS 2003; 17:1179-1193.
6. Smith CJ, Levy I, Sabin CA, et al. Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population. HIV Med 2004; 5:88-92.
7. Santos J, Palacios R, Gonzalez M, et al. Atherogenic lipid profile and cardiovascular risk factors in HIV-infected patients (Netar Study). Int J STD AIDS 2005; 16:677-680.
8. Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study. HIV Med 2006; 7:404-410.
9. Kaplan RC, Kingsley LA, Sharrett AR, et al. Ten-year predicted coronary heart disease risk in HIV-infected men and women. Clin Infect Dis 2007; 45:1074-1081.
10. Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the Multicenter AIDS Cohort Study. Arch Int Med 2005; 165:1179-1184.
11. Bonfanti P, Ricci E, de Socio G, et al. Metabolic syndrome: a real threat for HIV-positive patients? Results from the SIMONE study. J Acquir Immune Defic Syndr 2006; 42:128-131.
12. Holmberg SD, Moorman AC, Williamson JM, et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360:1747-1748.
13. Depairon M, Chessex S, Sudre P, et al. Premature atherosclerosis in HIV-infected individuals: focus on protease inhibitor therapy. AIDS 2001; 15:329-334.
14. Mondy K, Overton ET, Grubb J, et al. Metabolic syndrome in HIV-infected patients from an urban, Midwestern US outpatient population. Clin Infect Dis 2007; 44:726-734.
15. Dolan SE, Hadigan C, Killilea KM, et al. Increased cardiovascular disease risk indices in HIV-infected women. J Acquir Immune Defic Syndr 2005; 39:44-54.
16. Riddler SA, Li X, Chu H, et al. Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007; 8:280-287. This study provides a longitudinal description of lipid levels in participants in the MACS study, before and after HIV seroconversion and after initiation of HAART.
17. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease. J Clin Endocrin Metabol 2007; 92:2506-2512. The authors of this study show that both myocardial infarction rates and traditional CVD risk factors are increased in those with HIV infection compared with uninfected controls, although information was incomplete smoking.
18. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97:1837-1847.
19. De Socio GV, Martinelli L, Morosi S, et al. Is estimated cardiovascular risk higher in HIV-infected patients than in the general population? Scand J Infect Dis 2007; 39:805-812.
20. Friis-Moller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 2007; 45:1082-1084.
21. Mehta N, Reilly M. Atherosclerotic cardiovascular disease risk in the HAART-treated HIV-1 population. HIV Clin Trials 2005; 6:5-24.
22. Law MG, Friis-Moller N, El-Sadr WM, et al. The use of the Framingham equation of predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D study. HIV Med 2006; 7:218-230.
23. Knobel H, Jerico C, Montero M, et al. Global cardiovascular risk in patients with HIV infection: concordance and differences in estimates according to three risk equations (Framingham, SCORE, and PROCAM). AIDS Patient Care STDs 2007; 21:452-457. The authors report that the Framingham score generally overestimates CVD risk in those with HIV infection when compared with the PROCAM or SCORE risk equations.
24. Jacobson DL, Tang AM, Spiegelman D, et al. Incidence of metabolic syndrome in a cohort of HIV-infected adults and prevalence relative to the US population (National Health and Nutrition Examination Study). J Acquir Immune Defic Syndr 2006; 43:458-466.
25. Wand H, Calmy A, Carey DL, et al. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. AIDS 2007; 21:2445-2453.
26. Bonfanti P, Giannattasio C, Ricci E, et al. HIV and metabolic syndrome: a comparison with the general population. J Acquir Immune Defic Syndr 2007; 45:426-431.
27. Yan ZQ, Hansson GK. Innate immunity, macrophage activation, and atherosclerosis. Immunol Rev 2007; 219:187-203.
28. Richter A, Pladevall M, Manjunath R, et al. Patient characteristics and costs associated with dyslipidaemia and related conditions in HIV-infected patients: a retrospective cohort study. HIV Med 2005; 6:79-90.
29. Shah M, Tierney K, Adam-Huet B, et al. The role of diet, exercise and smoking in dyslipidaemia in HIV-infected patients with lipodystrophy. HIV Med 2005; 6:291-298.
30. David MH, Hornung R, Fichtenbaum CJ. Ischemic cardiovascular disease in persons with human immunodeficiency virus infection. Clin Infect Dis 2002; 34:98-102.
31. Hadigan C, Meigs J, Corcoran C, et al. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy. Clin Infect Dis 2001; 32:130-139.
32. Currier JS, Taylor A, Boyd F, et al. Coronary heart disease in HIV-infected individuals. J Acquir Immune Defic Syndr 2003; 33:506-512.
33. The Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349:1993-2003.
34. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-1735. A large prospective study that suggests that different classes of antiretroviral drugs may be associated with a different degree of CVD risk.
35. Iloeje UH, Yuan Y, L'Italien G, et al. Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients. HIV Med 2005; 6:37-44.
36. Mensah GA, Dietz WH, Harris VB, et al. Prevention and control of coronary heart disease and stroke: nomenclature for prevention approaches in public health: a statement for Public Health Practice from the Centers for Disease Control and Prevention. Am J Prevent Med 2005; 29:152-157.
37. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTER-HEART study): case-control study. Lancet 2004; 364:937-952.
38. Rosengren A, Hagman M, Wedel H, Wilhelmsen L. Serum cholesterol and long-term prognosis in middle-aged men with myocardial infarction and angina pectoris: a 16-year follow-up of the Primary Prevention Study in Gateborg, Sweden. Eur Heart J 1997; 18:754-761.
39. Thomsen TF, McGee D, Davidsen M, Jørgensen T. A cross-validation of risk-scores for coronary heart disease mortality based on data from the Glostrup Population Studies and Framingham Heart Study. Int J Epidemiol 2002; 31:817-822.
40. Cooper JA, Miller GJ, Humphries SE. A comparison of the PROCAM and Framingham point-scoring systems for estimation of individual risk of coronary heart disease in the Second Northwick Park Heart Study. Atherosclerosis 2005; 181:93-100.
41. Wu Y, Liu X, Li X, et al. Estimation of 10-year risk of fatal and nonfatal ischemic cardiovascular diseases in Chinese Adults. Circulation 2006; 114:2217-2225.
42. Worm SW, Sabin C, Reiss P, et al. Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components: data from the D:A:D Study. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California, USA. Abstract 815.
43. Dubé MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37:613-627.
44. Korthuis PT, Asch SM, Anaya HD, et al. Lipid screening in HIV-infected veterans. J Acquir Immune Defic Syndr 2004; 35:253-260.
45. Sabin C, Weber R, Fontas E, et al. Underutilization of recommended interventions for prevention of cardiovascular disease in HIV-infected patients with established cardiovascular disease or diabetes. In: Program and Abstracts of the 14th Conference on Retroviruses and Opportunistic Infections; 25-28 February 2007; Los Angeles, California, USA. Abstract 816.
46. Grover SA, Coupal L, Zowall H, et al. Evaluating the benefits of treating dyslipidemia: the importance of diabetes as a risk factor. Am J Med 2003; 115:122-128.
47. Glass TR, Weber R, Vernazza PL, et al. Ecological study of the predictors of successful management of dyslipidemia in HIV-infected patients on ART: the Swiss HIV Cohort Study. HIV Clin Trials 2007; 8:77-85. An interesting paper that identifies factors associated with achieving total cholesterol goals in clinical practice.
48. Fitch KV, Anderson EJ, Hubbard JL, et al. Effects of a lifestyle modification program in HIV-infected patients with the metabolic syndrome. AIDS 2006; 20:1843-1850.